| Recruitment status | Terminated |
| Unique ID issued by UMIN | UMIN000039356 |
| Receipt No. | R000044835 |
| Scientific Title | Assessment of AMPA receptor density in patients with schizophrenia: a cross-sectional [11C]K-2 PET study |
| Date of disclosure of the study information | 2020/02/03 |
| Last modified on | 2020/08/07 (Ver. 2) |
| Basic information | ||
| Public title | Measurement of AMPA receptor density in patients with schizophrenia: a PET study | |
| Acronym | AMPA PET study in patients with schizophrenia | |
| Scientific Title | Assessment of AMPA receptor density in patients with schizophrenia: a cross-sectional [11C]K-2 PET study | |
| Scientific Title:Acronym | AMPA PET study in patients with schizophrenia | |
| Region |
|
|
| Condition | |||
| Condition | Schizophrenia | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | To identify brain regions that show association between AMPA receptor density and illness severity |
| Basic objectives2 | Pharmacokinetics |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | Explanatory |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | AMPA receptor density in the right middle temporal gyrus and right anterior cingulate gyrus and PANSS score |
| Key secondary outcomes | AMPA receptor density and scores in the following scales: Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR), Autism-Spectrum Quotient (AQ), Post-traumatic Stress Diagnostic Scale (PDS), Montgomery-Asberg Depression Rating Scale (MADRS), Hamilton Depression Rating Scale (HDRS),Y-BOCS
Adverse events during 7 days after administration of [11C]K-2 |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | NO |
| Dynamic allocation | NO |
| Institution consideration | Institution is not considered as adjustment factor. |
| Blocking | NO |
| Concealment | No need to know |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Diagnosis | |
| Type of intervention |
|
|
| Interventions/Control_1 | Radiopharmaceutical [11C] K-2 is administered once, intravenously at 370 MBq for 1 minute. | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | (1) Fulfilling the criteria of schizophrenia according to Structured Clinical Interview for DSM-IV, SCID-I/DSM-IV,Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition(DSM5),and International Statistical Classification of Diseases and Related Health Problems 10th Revison(ICD-10)
(2) Being capable of providing informed consent |
|||
| Key exclusion criteria | (1) being pregnant or breast-feeding, or wishing to become pregnant, (2) being sensitive to alcohol, (3) comorbidity of serious neurological illness, (4) history of epilepsy, (5) use of perampanel or topiramate within 4 weeks, (6) history of substance use disorder for the past 6 months, (7) positive result on urine screening of substances that cause dependence, (8) having a metal object or pace maker in the body, (9) inappropriate size of head, neck, or body for MRI scan, (10) having large tatoo, (11) suffering from serious claustrophobia, (12) presence of significant brain anomaly, (13) abnormal lab results as follows: serum creatinine level of >=1.5, AST of >=150, or ALT of >=150, (14) having participated in any clinical trial that included the use of unapproved nuclear test within 6 months, (15) having participated in any other clinical trial that included intervention, (16) being judged to be inappropriate for participation by a study medical doctor | |||
| Target sample size | 30 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Yokohama City University Hospital
|
||||||
| Division name | Anesthesiology | ||||||
| Zip code | 236-0004 | ||||||
| Address | 3-9 Fukuura,Kanazawa-ku,Yokohama,Kanagawa,J apan | ||||||
| TEL | 045-787-2579 | ||||||
| johney4@hotmail.com | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Yokohama City University, School of Medicie | ||||||
| Division name | Physiology | ||||||
| Zip code | 236-0004 | ||||||
| Address | 3-9 Fukuura,Kanazawa-ku,Yokohama,Kanagawa,Japan | ||||||
| TEL | 045-787-2579 | ||||||
| Homepage URL | |||||||
| eirotuyosi@gmail.com | |||||||
| Sponsor | |
| Institute | Department of Physiology,Yokohama City University, School of Medicie |
| Institute | |
| Department | |
| Funding Source | |
| Organization | japan agency for medical research and development Strategic Research Program for Brain Science,Takeda Science Foundation,Yokohama City University Hospital advanded medical |
| Organization | |
| Division | |
| Category of Funding Organization | Non profit foundation |
| Nationality of Funding Organization | Japan |
| Other related organizations | |
| Co-sponsor | Keio University Hospital,Kyusyu University Hospital,Fukui University Hospital |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Yokohama City University Certified Institutional Review Board |
| Address | 3-9 Fukuura,Kanazawa-ku,Yokohama,Kanagawa,Japan |
| Tel | 045-370-7627 |
| ycu_crb@yokohama-cu.ac.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 横浜市立大学附属病院(神奈川県)、慶應義塾大学病院(東京都)、九州大学病院(福岡県)、福井大学病院(福井県) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Terminated | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Other | |
| Other related information | Because this study is described in the jRCT |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000044835 |